Phase 2 N=58 OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control Rate at 12 Weeks — 6; 6 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=7 IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia
Von Willebrand Disease
Primary: >50% Reduction in PBAC (Pictorial Blood Assessment Chart) at 6 Months — 71 percentage of participants
Phase 2 N=30 Diabetes in Neuropsychiatric Disorders
Schizophrenia
Primary: Body Mass Index — 22.1; 23.5; 24.2; 24.3 kg/m^2 — p=<0.001
Phase 2 N=8 Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
Proliferative Diabetic Retinopathy
Primary: The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) — -83.8; 52.6; 11.3; 55.4…
Phase 2 N=161 A Clinical Study to Evaluate the Effect of Naturlose (Tagatose)
Type 2 Diabetes
Primary: Change From Baseline HbA1c After Six Months of Treatment in Patients With Type 2 Diabetes Mellitus — 10; 7; 12 participants — p=<0.05
Phase 2 N=30 Treatment of Knee Osteoarthritis With Allogenic Mesenchymal Stem Cells
Osteoarthritis, Knee · Arthritis of Knee · Knee Osteoarthritis
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 14; 13 participants
Phase 2 N=95 A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Primary: To Establish the Safety, Tolerability, and RP2D (Phase 1); To Assess the Overall Response Rate in Subjects With Advanced Multiple Myeloma (Phase 2). — 95; 3; 3; 3…
Phase 2 N=12 Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder
Argininosuccinic Aciduria · Amino Acid Metabolism, Inborn Errors · Urea Cycle Disorders
Primary: Measures of Liver Function: AST and ALT — 36.2; 52; 31.7; 57.86 IU/L
Phase 2 N=18 Optimizing Pharmacotherapy for Bipolar Alcoholics
Bipolar Disorder · Alcohol Dependence
Primary: Mean Number of Standard Drinks Per Drinking Day During the Last 4 Weeks of the Trial — 0.6; 3.8 standard drinks/drinking day
Phase 2 N=19 Intranasal Oxytocin in the Treatment of Autism
Autism
Primary: Clinical Global Impressions Scale - Improvement - Social — 3; 1 participants
Phase 2 N=29 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
Alzheimer's Disease
Primary: Effects of MSDC-0160 on Cerebral Metabolic Glucose Rate or Placebo Over 12 Weeks in Pre-specified Regions of Interest Analysis Referenced to Cerebellum — 0.01; -0.02…
Phase 2 N=38 A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR) — 39.5 percentage of participants
Phase 2 N=93 Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis
Blepharitis
Primary: Visual Analogue Scale (VAS - Ranges 0-100 mm) — 36.5; 28.5 units on a scale (from 0 to 100 mm) — p=0.072
Phase 2 N=94 Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Lung Cancer
Primary: Counts of ≥ Grade 3 Adverse Events (AE) Graded by CTCAE v4 (Common Terminology Criteria for Adverse Events) That Are Definitely, Probably, or Possibly Related to…
Phase 2 N=40 Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment
Chronic Idiopathic Urticaria
Primary: Observed Values and Absolute Change From Baseline in FceRI Positive Skin Cells: Dermis, Lesional and Non Lesional Skin — 18.14; 15.17; 13.40; 20.19 FcεRI positive skin…